Merck disclosed mixed data for remigromig, its ophthalmology candidate targeting diabetic macular edema. The therapy met the primary endpoint in a pivotal study but the full results raised questions among analysts about remigromig’s commercial prospects. The situation illustrates a recurring theme in ophthalmic development: meeting a primary endpoint does not automatically translate into market advantage, particularly if secondary endpoints, durability, switching patterns, or safety/retention profiles do not clearly separate from incumbents or pipeline rivals. For biotech investors and product strategists, the update is a near-term read-through on how clearly remigromig may differentiate versus existing biologics and non-biologic options in a crowded retina market where pricing and payer coverage can hinge on broader outcome signals beyond the primary analysis.